The marijuana stock market has been making headlines for some time now. As so many new laws come into place and the ecosystem surrounding cannabis becomes more friendly to investors, it seems as though the uptick in those choosing to put money into marijuana is well on its way.
The U.S. and Canada have become the two primary sources for investing in the industry. Although marijuana is still very much illegal from the federal level, the government has taken a very hands-off approach to legislate individual state laws on cannabis. This means that companies have been able to make big moves in the present day.
To our north, Canada has also been one of the largest players in the world for marijuana, being the first nation to legalize the substance for recreational purposes. Canada very quickly saw its legislation act as a domino effect for the rest of the industry, which has made investing easier than ever.
Next Green Wave (NXGWF) (NGW) has become one of the leading producers of vertically integrated high quality cannabis. Since the end of December of last year, Next Green Wave’s stock has shot up by more than 80%, which continues to show the amount of investor faith there is in vertical integration.
In recent news for the company, CEO Leigh Hughes stated that Next Green Wave is working to enter the Colombian market on cannabis. He stated that their newest deal with Organic Medical Growth is “is focused on producing and commercializing medical cannabis throughout Columbia.” As more and more companies continue to move into the abroad market on marijuana, it seems as though the international space is full of opportunity.
Hughes went on to state that “as we know to be able to provide premium product into the market, you need to have a strong skillset. Organic Medical Growth saw Next Green Wave as a great pioneer to compliment their nursery and manufacturing skills.” The hopes are that Next Green Wave can continue to bring cannabis into the future of the industry.
GW Pharmaceuticals (GWPH) is one of the leading marijuana-derived pharmaceutical companies in the industry. GW Pharmaceuticals has also seen a large amount of press over the course of the past several years given a series of new drugs they have put out. Their claim to fame however, Epidiolex, became the first drug made from cannabis to be approved by the FDA in the U.S., which was quite a large milestone. Epidiolex is used in the treatment of various seizure disorders and has been hailed as being a massive breakthrough for those who need it.
GW Pharmaceutical however occupies an area of the market that is known as ancillary due to the fact that they do not touch the physical cannabis plant. The company however, can be a solid choice for some who wish to have less of a risk with their investments than the all too volatile marijuana sector. GW Pharmaceuticals remains an interesting company to watch as we continue to traverse the future of the cannabis industry.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), Midam Ventures LLC and Next Green Wave (NGW), Midam has been paid $150,000 from Next Green Wave (NGW) for a period from October 1, 2018 to November 8, 2018. Midam has been compensated an additional $100,000 and has extended its period of coverage to December 8, 2018. Midam has been compensated an additional $75,000 and has extended its period of coverage to January 8, 2019. Midam has been compensated an additional $50,000 and has extended its period of coverage to February 8, 2019. We may buy or sell additional shares of (NGW) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Next Green Wave.